Pulmonary Tuberculosis Clinical Trials Analysis Report 2025 - Regional & Country-Specific Trial Data, Trial Phases, Statuses, Endpoint Statuses, Sponsor Types

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Aug. 29, 2025 (GLOBE NEWSWIRE) -- The "Pulmonary Tuberculosis - Global Clinical Trials Review, 2025" has been added to ResearchAndMarkets.com's offering.

The report offers an in-depth analysis of the clinical trials landscape for Pulmonary Tuberculosis worldwide. This insightful document compiles and evaluates top-line data connected to Pulmonary Tuberculosis clinical trials, detailing trial numbers and average enrollments across leading countries. The report extensively covers various aspects, including regional and country-specific trial data in G7 and E7 nations, trial phases, statuses, endpoint statuses, and sponsor types.

Additionally, it highlights key drugs currently going through trials, based on the number of ongoing studies. This analysis is derived from the analyst's proprietary database, curated through diverse global sources such as 80+ clinical trial registries, conferences, journals, and relevant news, with periodic updates ensuring real-time accuracy.

The data presented is designed to significantly improve decision-making capabilities, offering strategies to gain a competitive edge in the market. The report's proprietary insights also assist stakeholders in devising effective counter strategies.

Report Scope:

• A detailed snapshot of the global clinical trials environment is provided.
• It includes top-level data on trials segmented by region, country (G7 & E7), trial phase, status, sponsor type, and endpoint status.
• Comprehensive reviews of prominent companies and their respective trials, categorized by trial title, phase, and status.
• Analyzes uncompleted trials (terminated, suspended, and withdrawn), outlining reasons for their status.
• Offers insights into enrollment trends over the past five years.
• Includes recent news updates from the past three months.

Reasons to Buy:

• Assists in developing strategic business strategies, emphasizing investment insights.
• Helps pinpoint optimal locations for conducting clinical trials, leading to time and cost efficiency.
• Provides top-level analysis of the Global Clinical Trials Market, identifying crucial business opportunities.
• Enhances understanding of trial counts and enrollment patterns by country within the global therapeutics industry.
• Enables interpretation of clinical trial success rates by comparing completed and incomplete (terminated, suspended, withdrawn) trials.
• Facilitates a comprehensive assessment of trial indications on global, regional, and country levels.

A selection of companies mentioned in this report includes, but is not limited to:

• Johnson & Johnson
• Otsuka Holdings Co Ltd
• GSK plc
• IQVIA Holdings Inc
• Pharmasyntez
• PT Kimia Farma Tbk
• Sanofi
• LigaChem Biosciences Inc
• Cadila Pharmaceuticals Ltd
• Sequella Inc

For more information about this clinical trials report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN29082025004107003653ID1109992310